Abstract. The metabolism of arachidonic acid by either cyclooxygenase or lipoxygenase is believed to play an important role in carcinogenesis. Leukotriene (LT) D 4 is a proinflammmatory mediator derived from arachidonic acid through various enzymatic steps, and 5-lipoxygenase is an important factor in generating LTD 4 . We investigated LTD 4 receptor (cysteinyl LT 1 receptor: CysLT 1 R) expression in prostate cancer (PC), as well as the effects of CysLT 1 R antagonist on cell proliferation in PC cell lines. CysLT 1 R expression in PC patients, prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH), and normal prostate (NP) tissues were examined. CysLT 1 R expression was detected by immunohistochemistry. Effects of CysLT 1 R antagonist on PC cell growth were examined by MTT assay. Flow cytometry and Hoechst staining were used to determine whether or not the CysLT 1 R antagonist induces apoptosis. Initially, only slight CysLT 1 R expression was detected in BPH and NP tissues and marked CysLT 1 R expression was detected in PIN and PC tissues. CysLT 1 R expression was higher in high-grade cancer than in low-grade cancer. Furthermore, CysLT 1 R antagonist caused marked inhibition of PC cells in a concentration-and time-dependent manner through early apoptosis. In conclusion, CysLT 1 R is induced in PC, and the results suggest that CysLT 1 R antagonist may mediate potent anti-proliferative effects of PC cells. Thus, the target of CysLT 1 R may become a new therapy in the treatment of PC.
Introduction
Prostate cancer (PC) in American men statistically comprises 32% of all cancers, including lung and colon cancers, and is increasing world-wide. Prostate cancer differs from other urinary tract tumors due to hormone dependency. With respect to the metastasis of cancer cells, angiogenetic factors play an important role in this organ as in others (1) . Although various potential angiogenetic factors have been identified in PC, it is still unclear by which process PC cells become angiogenic.
The metabolism of arachidonic acid (AA) by either the cyclooxygenase (COX) pathway or the lipoxygenase (LOX) pathway generates eicosanoids, which have been implicated in the pathogenesis of a variety of human diseases, including cancer, and are significantly involved in tumor promotion, progression, and metastasis. Studying these pathways in specimens from patients with PC, we demonstrated that COX-2 and 5-LOX were overexpressed in PC tissues (2, 3) . Leukotriene (LT) belongs to an important group of proinflammatory mediators, and LT is synthesized by AA via the 5-LOX pathway. The activity of 5-LOX leads to the formation of unstable LTA 4 , which can be converted into either LTB 4 , or cysteinyl (Cys) LTs (LTC 4 , LTD 4 and LTE 4 ). LTD 4 is the most important component of CysLTs (CysLT 1 , CysLT 2 ) and CysLT 1 receptor (CysLT 1 R) is specific for LTD 4 (4) . Generally, CysLTs are important mediators of human bronchial asthma and many CysLTs receptor antagonists are clinically used in treating human bronchial asthma. A few studies have addressed the relationship between CysLT 1 R and colon cancer (5, 6) . To date, no study has addressed the relationship between CysLT 1 R and human PC. Our team has already demonstrated that 5-LOX is overexpressed in human urological cancer (3, (7) (8) (9) .
With this background, the purpose of our study was to examine the expression of CysLT 1 R in human PC tissues and PC cell lines, to evaluate the inhibitory effect of CysLT 1 R antagonist on human PC cell lines, and to determine whether 
Materials and methods
Tumor specimens. Tumor specimens were obtained from 151 patients with PC, 20 with prostatic intraepithelial neoplasia (PIN), 20 with benign prostatic hyperplasia (BPH), and 20 patients with normal prostate tissues (NP) who underwent total cystectomy due to bladder cancer. The 151 patients were aged 53-86 years (mean age 69±7.5 years). The tumor histopathologies were classified using Gleason score as follows: low group, ≤5; middle group, 6 and 7; high group, ≥8. There were 49 patients in the low group, 57 in the middle group, and 45 in the high group. The age of the 20 patients with PIN averaged 66±6.1 (52-73) years, and that of the 20 patients with BPH averaged 67±5.6 (59-76) years, and all had nodular hyperplasia. The age of the 20 patients with NP averaged 67±1.1 (54-79) years (Table I) . Their prostate volumes were normal size (volume: <25 cm 3 ). Tumor tissues, non-tumor tissues, vascular endothelium, and interstitial tissues from the subjects were immunostained with antibodies for CysLT 1 R.
Immunohistochemistry and patient samples. PC, PIN, BPH and NP tissue specimens were preserved in 10% formalin and embedded in paraffin, serially sectioned onto microscope slides at a thickness of 4 μm, and then deparaffinized. Immunohistochemical staining was performed with the VectaStain avidin-biotin peroxidase complex kit (Vector Laboratories; Burlingame, CA, USA) as previously described (10) . Primary antibodies against goat CysLT 1 R (Abcam, Cambridge, UK) were diluted 1:50 with 1% bovine serum albumin in phosphatebuffered saline (PBS), and left with the sample for 1 h at room temperature. Similar staining with non-immune goat serum was performed as a negative control.
Immunohistochemical analysis. For each tissue specimen, the extent and intensity of staining with anti-CysLT 1 R antibody was graded on a scale of 0-4 by two observers in a blinded manner on two separate occasions using coded slides, and an average score was calculated. Staining was classified into five grades 0-4 according to the intensity of staining and the number of positive cells (10) . Observers assessed all tissues to assign the score. Scale 4 implied all staining was maximally intense throughout the specimen, while scale 0 implied staining was absent throughout the specimen. The microanatomical sites of staining were also recorded. In order to quantify the expressions of CysLT 1 R, the same two pathologists made assessments throughout the study, staining control specimens simultaneously, so as to increase the credibility of data. In addition, all specimens were re-assessed, which also contributes to excluding subjective variability.
Reagents and materials. RPMI-1640 was purchased from Nissui Pharmaceutical Company (Tokyo, Japan). Fetal bovine serum (FBS) and penicillin-streptomycin mixture were from Biowhitteker (Walkersville, MD, USA). Trypsin/EDTA was from Gibco BRL (Rockville, MD, USA). Montelukast is a selective CysLT 1 R antagonist (LKT laboratories, Inc., MN, USA).
Cell cultures. The human PC cell lines LNCaP, PC-3, DU-145 and normal stromal prostate cell lines (NPCs) were obtained from Health Science Research Resources Bank (HSRRB, Osaka, Japan). Cells were grown in culture flask (Nunc, Roskilde, Denmark) in RPMI-1640 supplemented with 10% FBS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin, in a humidified 5% CO 2 atmosphere at 37˚C. The media were changed every 3 days, and the cells were separated via trypsinization using trypsin/EDTA when they reached subconfluence.
Cell-proliferative studies. Cells (~1.0x10 4 ) placed onto 8x8 mm diameter multichamber slides (Nunc, Copenhagen, Denmark) were treated with CysLT 1 R antagonist dissolved in ethanol. The final concentration of ethanol was <0.05%. Cell viability was measured at day 1 by a microplate reader using a modified 3-[4,5-dimethylthiazol-2-thiazolyl]-2,5-diphenyltetrazolium bromide (MTT) assay (WST-1 assay; Dojindo, Kumamoto, Japan), and presented as the percentage of control-culture conditions.
Flow cytometry
Annexin V and propidium iodide staining. The effects of CysLT 1 R antagonist on PC cells were determined by dual staining with Annexin V-FITC and propidium iodide using Annexin V-FITC apoptosis detection kit I (Biosciences Pharmingen). Annexin V-FITC and propidium iodide (PI) were added to the cellular suspension as in the manufacturer's instructions, and sample fluorescence of 10000 cells was analyzed by flow cytometry, FACScan (Becton Dickinson, Germany). Cells which were Annexin V-FITC-positive and PI-negative were identified as early apoptosis. Cells which were Annexin V-FITC-positive and PI-positive were identified as late apoptosis or necrosis.
Identification of DNA fragmentation. The assay was performed by the TdT-mediated dUTP nick-end labelling (TUNEL) method using APO-Direct TM kit (Becton Dickinson). Table I . Summary of the various tumor specimens. 
The tumor histopathologies were diagnosed by pathologists at the Department of Pathology. Detection of apoptosis. DNA chromatin morphology was assessed using Hoechst staining. PC cells were incubated with 100 μM CysLT 1 R antagonist for 24 h. Cells were washed by RPMI-1640 and labeled with 8 mg/ml of Hoechst 33342 (Sigma-Aldrich Japan K.K., Tokyo, Japan) for 10 min; PI (Sigma-Aldrich Japan K.K.) was added (10 mg/ml final concentration), and the cells were examined by fluorescence microscopy.
Statistical analysis.
All results are presented as the mean ± SD. Analysis of data was performed using the analysis of variance (ANOVA) (11) .
Results
CysLT 1 R expression of prostate tissues. To examine the expression and localization of CysLT 1 R in NP, BPH, PIN and PC tissues (Fig. 1B) immunohistochemistry was performed.
Very weak CysLT 1 R expression was found in BPH and NP cases (Fig. 1A) . In contrast, significantly strong CysLT 1 R expression was observed in cancer tissues including nuclei and cytoplasm in all PC groups ( Fig. 1C ; Low group, 1D; Middle group, 1E; High group) and PIN group (Fig. 1F) . Immunostaining with PBS was negative in all subjects (data not shown).
Statistical analysis of CysLT 1 R expression.
The extent and intensity of staining of PC tissues using CysLT 1 R antibody were scaled 0-4 by two observers in a blinded manner. CysLT 1 R expression was significantly more extensive and intense in all PC groups (All groups, 2.6±1.0; Low group, 2.1±0.8; Middle group, 2.7±0.9; High group, 3.2±0.8) and PIN tissues (1.8±0.9) than in tissues of BPH (1.3±0.5) and NP tissues (1.2±0.1) only the epithelium (Table II) . CysLT 1 R expression was higher in High group cancer than Low group cancer (Table III) . However, CysLT 1 R expression in blood vessels and stromal tissues were at basic levels in PC, PIN, BPH and NP tissues (Table II) . Table II . Statistical analysis of CysLT 1 R expression. 
CysLT 1 R antagonist-induced growth inhibition in PC cells

-------------------------------------------------Epithelium Blood vessel Stromal tissue -------------------------------------------------
-------------------------------------------------
Scaled 0-4 on the coded sections by two observers in a blinded manner. 0, no staining; 4, maximum intensity. Statistical analysis was performed using the ANOVA (p-value). Only epithelium, CysLT 1 R expression was significantly more extensive and intense in PC and PIN tissue than BPH and NP tissues. However, CysLT 1 R expression in blood vessels and stromal tissues were at the basic level in PC, PIN, BPH and NP tissues ( a P<0.01). 
-------------------------------------------------P-value (ANOVA) PC -----------------------------------Epithelium Low group Middle group High group -------------------------------------------------
-------------------------------------------------
on PC cell proliferation, we analyzed cell viability in vitro by modified MTT assay. As shown in Fig. 2 , although CysLT 1 R antagonist had no effect on NPC proliferation, CysLT 1 R antagonist induced the reduction of cell viability with the half-maximal concentration of growth inhibition of all PC cell lines (LNCaP, PC-3, DU-145) ( Fig. 2A) in the range of 12.5-100 μM. Furthermore, counting cells at days 1 and 2 clearly showed marked inhibition of cell proliferation using 100 μM of CysLT 1 R antagonist (Fig. 2B) . CysLT 1 R antagonist stopped the growth of all PC cells.
CysLT 1 R antagonist-induced apoptosis by flow cytometry.
To evaluate whether or not cell death induced by CysLT 1 R antagonist was through apoptosis, we used flow cytometry. All PC cell lines and NPCs without CysLT 1 R antagonist are shown in Fig. 3 . Almost all PC cells (LNCaP, PC-3, DU-145) with treatment of 100 μM CysLT 1 R antagonist induced early apoptosis. However, NPCs with treatment of 100 μM CysLT 1 R antagonist could not induce apoptosis (Fig. 3) .
Furthermore, 100 μM CysLT 1 R antagonist induced DNA fragmentation in all PC cells. However, 100 μM of CysLT 1 R antagonist could not induce DNA fragmentation in NPCs (Fig. 4) .
Effect of CysLT 1 R antagonist in induction of apoptosis on human PC cells.
To evaluate whether or not cell death induced by CysLT 1 R antagonist was through apoptosis, we evaluated the chromatin morphology of PC cells using Hoechst 33342 staining. Cells treated with CysLT 1 R antagonist showed significant chromatin condensation, cellular shrinkage, small membrane-bound bodies (apoptotic bodies), and cytoplasmic condensation. These cellular changes are typical characteristics of apoptosis (Fig. 5B, LNCaP ; 5D, PC-3; 5F, DU-145). All PC cell lines without CysLT 1 R antagonist maintained normal chromatin patterns and cell size (Fig. 5A , LNCaP; 5C, PC-3; 5E, DU-145).
Discussion
LTs are biologically active fatty acids derived from the oxidative metabolism of AA (12, 13) , and they are derived from AA via 5-LOX pathway. The activity of 5-LOX leads to the formation of unstable LTA 4 , which can be converted into either LTB 4 , or CysLTs (LTC 4 , LTD 4 and LTE 4 ). CysLTs are components of a slow-reacting substance of anaphylaxis. cancers and 5-LOX inhibitor may attenuate growth of human urological cancers and induced apoptosis through AA pathway (3, (7) (8) (9) 15) .
With this background, we examined whether or not CysLT 1 R would be expressed in human PC tissues, and whether or not it would prevent PC cell growth as CysLT 1 R antagonist.
We found CysLT 1 R strongly expressed in PC tissues. The extent and intensity of CysLT 1 R expression in PC tissues were greater than in NP tissues. Furthermore, CysLT 1 R expression was higher in high group cancer than low group cancer. Next, we demonstrated that co-incubation of PC cells with CysLT 1 R antagonist stopped the growth of PC cells and potently inhibited cell growth in a dose-and time-dependent manner by MTT assay. These results indicate that CysLT 1 R is essential for cell growth of PC cells. The mechanism by which CysLT 1 R antagonist induces growth prevention in PC cells needed clarification. To address this problem, we examined whether or not apoptosis was involved in growth suppression in such cancer cells. CysLT 1 R antagonist (100 μM) strongly induced early apoptosis in all PC cells by flow cytometry and Hoechest staining. Our results demonstrated that apoptosis may be involved in the mechanisms by CysLT 1 R antagonist to prevent cell growth in PC cells. Thus, our research provides the first confirmation that through apoptosis CysLT 1 R antagonist inhibits prostate cancer cell growth.
Regarding CysLT 1 R and colon cancer, Ohd et al have reported that CysLT 1 R is overexpressed in human colorectal cancer and CysLT 1 R is significantly correlated to COX-2, 5-LOX (5). The expression of CysLT 1 R is higher in high-grade and early-stage carcinoma, suggesting typical differences in each cancer. Survival time is slightly shorter in patients with high-intensity CysLT 1 R staining than in those with lowintensity staining. This result indicates a relationship between patient survival and the expression of CysLT 1 R. These studies support the data that CysLT 1 R antagonist can prevent cancer cell growth.
In summary, our study provides evidence that cell growth and apoptosis of human PC cells are regulated by CysLT 1 R. Growth inhibition of PC cells by blocking CysLT 1 R was associated with induction of apoptosis. Thus, CysLT 1 R antagonist provides a novel approach to anti-cancer therapies.
